Robert Wasserman
Stock Analyst at Benchmark
(3.40)
# 962
Out of 5,156 analysts
119
Total ratings
50.46%
Success rate
3.15%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITGR Integer Holdings | Upgrades: Buy | $95 | $85.38 | +11.27% | 13 | Feb 20, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $75 → $90 | $68.14 | +32.08% | 11 | Feb 19, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $175 → $220 | $208.16 | +5.69% | 12 | Nov 7, 2025 | |
| PRLB Proto Labs | Maintains: Buy | $45 → $55 | $57.59 | -4.50% | 7 | Nov 3, 2025 | |
| INTS Intensity Therapeutics | Maintains: Speculative Buy | $100 → $38 | $7.77 | +382.63% | 7 | Aug 20, 2025 | |
| TECH Bio-Techne | Reiterates: Buy | $75 | $54.87 | +36.69% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $9.02 | +66.39% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.95 | +207.69% | 9 | May 12, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $27.45 | +27.50% | 1 | Apr 17, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $3.52 | - | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $19.90 | +50.75% | 6 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $4.01 | +24.69% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $8.35 | +43.71% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.25 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $127.89 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $3.55 | +12.68% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $100 | $2.80 | +3,471.43% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $3.37 | +2,125.52% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $198.80 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $509.97 | +13.73% | 1 | Jul 16, 2021 |
Integer Holdings
Feb 20, 2026
Upgrades: Buy
Price Target: $95
Current: $85.38
Upside: +11.27%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Buy
Price Target: $75 → $90
Current: $68.14
Upside: +32.08%
Ligand Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $175 → $220
Current: $208.16
Upside: +5.69%
Proto Labs
Nov 3, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $57.59
Upside: -4.50%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $100 → $38
Current: $7.77
Upside: +382.63%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $54.87
Upside: +36.69%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $9.02
Upside: +66.39%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.95
Upside: +207.69%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $27.45
Upside: +27.50%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $3.52
Upside: -
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $19.90
Upside: +50.75%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $4.01
Upside: +24.69%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $8.35
Upside: +43.71%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $1.25
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $127.89
Upside: -
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $3.55
Upside: +12.68%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $100
Current: $2.80
Upside: +3,471.43%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $3.37
Upside: +2,125.52%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $198.80
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $509.97
Upside: +13.73%